Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the blood products, diabetes medication, biochemical medication, and chemical medicine businesses in China. It engages in the research and development, production, and sales of blood products comprising human fibrinogen, intravenous human immunoglobulin, rabies immunoglobulin, human albumin, human immunoglobulin, freeze-dried intravenous human immunoglobulin, and hepatitis B human...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive'
Target Price
The average target price of 300294.SZ is 31 and suggests 38% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell